Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Taplin ME, et al. Among authors: mathew p. Clin Cancer Res. 2009 Nov 15;15(22):7099-105. doi: 10.1158/1078-0432.CCR-09-1722. Epub 2009 Nov 3. Clin Cancer Res. 2009. PMID: 19887483 Free PMC article. Clinical Trial.
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Mathew P, et al. Clin Cancer Res. 2007 Oct 1;13(19):5816-24. doi: 10.1158/1078-0432.CCR-07-1269. Clin Cancer Res. 2007. PMID: 17908974 Clinical Trial.
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Rosenberg JE, et al. Among authors: mathew p. J Clin Oncol. 2009 Jun 10;27(17):2772-8. doi: 10.1200/JCO.2008.19.8002. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349545 Free PMC article.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: mathew p. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Lin SH, et al. Among authors: mathew p. Clin Cancer Res. 2008 Jun 15;14(12):3729-36. doi: 10.1158/1078-0432.CCR-08-0472. Clin Cancer Res. 2008. PMID: 18559590 Free PMC article.
693 results